# OM1, Inc.

> OM1 is a Boston healthcare data and technology company that combines longitudinal clinical datasets, AI-based patient phenotyping, registry automation and scientific services to help life sciences companies, providers and payers measure and predict patient outcomes.

- **Founded:** 2015
- **Headquarters:** Boston, United States
- **Founders:** Richard Gliklich (Founder; described as CEO in historical financing announcements)
- **Products:** PhenOM, OM1 Aspen, Clinical Datasets & Insights, Clinical Registries and Automated Studies, Scientific and Consulting Services
- **Notable:** Supported the real-world evidence program behind Hologic’s February 2026 Aptima HPV primary screening approval., Joint Insights was evaluated in randomized clinical trials published in JAMA Network Open (2021) and eClinicalMedicine (2025)., Received Frost & Sullivan’s 2024 North American New Product Innovation Award in real-world evidence analytics.

## Products & services

- **PhenOM** — Healthcare foundation model for digital phenotyping, patient finding and predictions of diagnoses, medical events and treatment outcomes; OM1 reports training on over one billion patient-years.
- **OM1 Aspen** — Automated observational study and registry platform launched in June 2023.
- **Clinical Datasets & Insights** — Licensable curated cohorts and linked longitudinal EMR, claims and specialty-network data.
- **Clinical Registries and Automated Studies** — Evidence generation programs including prospective registries and post-market research, with automated data abstraction.
- **Scientific and Consulting Services** — Epidemiology, data science, AI and regulatory strategy services for fit-for-purpose evidence programs.
- **Joint Insights** — AI-enabled knee osteoarthritis decision aid combining education, preferences and personalized outcome reports; evaluated in randomized trials.

## Achievements

- Supported the real-world evidence program behind Hologic’s February 2026 Aptima HPV primary screening approval.
- Joint Insights was evaluated in randomized clinical trials published in JAMA Network Open (2021) and eClinicalMedicine (2025).
- Received Frost & Sullivan’s 2024 North American New Product Innovation Award in real-world evidence analytics.
- Current company history page lists 10 awarded AI technology patents.

## Latest updates

- **2026-09** — Novartis described progress in the AAD collaboration using OM1 Patient Finder to study missed HS diagnosis opportunities and develop physician resources.
- **2026-05** — OM1 announced its role in the 650,000-plus-woman study supporting Hologic’s expanded FDA screening indication.

## Links

- Website: https://www.om1.com/
- LinkedIn: https://www.linkedin.com/company/om1-inc.
- Twitter/X: https://twitter.com/om1inc

---

Profile page: https://yespress.io/om1-inc
Published by YesPress — https://yespress.io
Last updated: 2026-10-05